Loading...
RAS mutations are ubiquitous in solid tumor malignancies and until recently were not thought to be druggable targets. Sotorasib is a small molecule KRAS G12C inhibitor that has demonstrated activity in non–small-cell lung cancer and, more recently, colorectal cancer.
Investigators now report results of an industry-sponsored, open-label, single-arm, phase 1–2 trial evaluating the safety and efficacy of oral sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer. The trial included 38 patients treated at 25 centers in 7 countries; median age was 66, most patients (76%) were men, most (82%) had hepatic metastases, and most (79%) had received two or more lines of prior chemotherapy.
The primary endpoint, centrally confirmed objective respons…